Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does mixed connective tissue disease exist? Yes.

Martin Aringer1, Günter Steiner, Josef S Smolen

  • 1Department of Rheumatology, Internal Medicine III, Medical University of Vienna, AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Rheumatic Diseases Clinics of North America
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Rheumatoid factor and anti-citrullinated protein IgA antibodies in the diagnosis, prognosis and monitoring of patients with rheumatoid arthritis.

Journal of translational autoimmunity·2025
Same author

Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond.

Current opinion in rheumatology·2024
Same author

Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach.

Frontiers in immunology·2023
Same author

The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis.

Frontiers in immunology·2023
Same author

Polysulfides derived from the hydrogen sulfide and persulfide donor P* inhibit IL-1β-mediated inducible nitric oxide synthase signaling in ATDC5 cells: are CCAAT/enhancer-binding proteins β and δ involved in the anti-inflammatory effects of hydrogen sulfide and polysulfides?

Nitric oxide : biology and chemistry·2022
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Mixed connective tissue disease (MCTD) is a distinct entity characterized by specific autoantibodies like U1-snRNP. This helps in diagnosing organ issues and differentiating it from other autoimmune diseases.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Mixed Connective Tissue Disease (MCTD) presents with overlapping features of rheumatoid arthritis, systemic sclerosis, and inflammatory myopathies.
  • A specific serologic marker, high titer IgG antibodies to U1 ribonucleoprotein (U1-snRNP), supports the concept of MCTD.
  • Understanding MCTD aids in predicting and diagnosing organ involvement and patient education.

Purpose of the Study:

  • To establish Mixed Connective Tissue Disease (MCTD) as a distinct disease entity.
  • To highlight specific serologic markers for MCTD diagnosis.
  • To differentiate MCTD from other connective tissue diseases like lupus and scleroderma.

Main Methods:

  • Analysis of serologic markers, including IgG antibodies to U1-snRNP and heterogeneous nuclear ribonucleoprotein (hnRNP)-A2.

Related Experiment Videos

  • Examination of the association between MCTD and HLA-DR4.
  • Clinical evaluation of patients with overlapping connective tissue disease features.

    • Main Results:

    • Autoantibodies to U1-snRNP and hnRNP-A2 show specificity for MCTD.
    • The association with HLA-DR4 distinguishes MCTD from systemic lupus erythematosus and systemic sclerosis.
    • These findings support MCTD as a unique disease entity.

    Conclusions:

    • The concept of Mixed Connective Tissue Disease (MCTD) is clinically useful for diagnosis and patient management.
    • Specific autoantibodies and genetic associations confirm MCTD as a distinct disease entity.
    • MCTD is not merely a mixture of undifferentiated collagen vascular diseases.